Apellis Pharmaceuticals Inc
APLS24.260USD
+1.310+5.71%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
3.06BMarket Cap
LossP/E TTM
More Details of Apellis Pharmaceuticals Inc Company
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Company Info
Ticker SymbolAPLS
Company nameApellis Pharmaceuticals Inc
IPO dateNov 09, 2017
CEODr. Cedric Francois, M.D., Ph.D.
Number of employees705
Security typeOrdinary Share
Fiscal year-endNov 09
Address100 Fifth Avenue
CityWALTHAM
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02451
Phone16179775700
Websitehttps://apellis.com/
Ticker SymbolAPLS
IPO dateNov 09, 2017
CEODr. Cedric Francois, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Cedric Francois, M.D., Ph.D.
Dr. Cedric Francois, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.61M
-4.95%
Dr. Pascal Deschatelets, Ph.D.
Dr. Pascal Deschatelets, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
1.12M
+1.15%
Mr. Alec Machiels, J.D.
Mr. Alec Machiels, J.D.
Independent Director
Independent Director
1.01M
-0.59%
Mr. David Osborne Watson, J.D.
Mr. David Osborne Watson, J.D.
General Counsel, Secretary
General Counsel, Secretary
112.58K
-4.25%
Ms. Nur Nicholson
Ms. Nur Nicholson
Chief Technical Operations Officer
Chief Technical Operations Officer
71.83K
+59.79%
Dr. Caroline Baumal, M.D.
Dr. Caroline Baumal, M.D.
Chief Medical Officer
Chief Medical Officer
41.19K
+557.11%
Mr. Craig A. Wheeler
Mr. Craig A. Wheeler
Independent Director
Independent Director
16.48K
--
Ms. Keli Walbert
Ms. Keli Walbert
Independent Director
Independent Director
9.09K
--
Ms. Stephanie Monaghan O'Brien, J.D.
Ms. Stephanie Monaghan O'Brien, J.D.
Independent Director
Independent Director
955.00
-86.25%
Mr. Niel Carnahan
Mr. Niel Carnahan
Investor Contact
Investor Contact
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Cedric Francois, M.D., Ph.D.
Dr. Cedric Francois, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.61M
-4.95%
Dr. Pascal Deschatelets, Ph.D.
Dr. Pascal Deschatelets, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
1.12M
+1.15%
Mr. Alec Machiels, J.D.
Mr. Alec Machiels, J.D.
Independent Director
Independent Director
1.01M
-0.59%
Mr. David Osborne Watson, J.D.
Mr. David Osborne Watson, J.D.
General Counsel, Secretary
General Counsel, Secretary
112.58K
-4.25%
Ms. Nur Nicholson
Ms. Nur Nicholson
Chief Technical Operations Officer
Chief Technical Operations Officer
71.83K
+59.79%
Dr. Caroline Baumal, M.D.
Dr. Caroline Baumal, M.D.
Chief Medical Officer
Chief Medical Officer
41.19K
+557.11%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
By BusinessUSD
Name
Revenue
Proportion
SYFOVRE
130.17M
78.04%
EMPAVELI
19.73M
11.83%
Licensing and other revenue
16.90M
10.13%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
SYFOVRE
130.17M
78.04%
EMPAVELI
19.73M
11.83%
Licensing and other revenue
16.90M
10.13%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Morningside Venture Investments, Ltd.
10.14%
Wellington Management Company, LLP
9.74%
Avoro Capital Advisors LLC
9.68%
EcoR1 Capital, LLC
9.42%
The Vanguard Group, Inc.
8.01%
Other
53.01%
Shareholders
Shareholders
Proportion
Morningside Venture Investments, Ltd.
10.14%
Wellington Management Company, LLP
9.74%
Avoro Capital Advisors LLC
9.68%
EcoR1 Capital, LLC
9.42%
The Vanguard Group, Inc.
8.01%
Other
53.01%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
47.44%
Investment Advisor
24.12%
Hedge Fund
15.28%
Research Firm
11.85%
Corporation
10.19%
Individual Investor
3.82%
Bank and Trust
1.65%
Pension Fund
1.30%
Private Equity
1.14%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
707
147.98M
117.74%
-16.68M
2025Q1
739
147.63M
117.48%
-17.38M
2024Q4
726
148.40M
118.39%
-6.44M
2024Q3
713
138.62M
113.64%
-12.05M
2024Q2
701
135.38M
111.32%
-9.63M
2024Q1
699
132.74M
109.77%
-12.51M
2023Q4
669
131.80M
110.59%
-13.78M
2023Q3
642
131.99M
111.79%
-7.62M
2023Q2
631
124.43M
106.07%
-15.68M
2023Q1
592
129.73M
111.79%
-2.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Morningside Venture Investments, Ltd.
12.81M
10.19%
--
--
Mar 31, 2025
Wellington Management Company, LLP
12.30M
9.79%
+502.40K
+4.26%
Mar 31, 2025
Avoro Capital Advisors LLC
12.22M
9.72%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
11.90M
9.46%
+4.96K
+0.04%
Mar 31, 2025
The Vanguard Group, Inc.
10.11M
8.05%
+84.33K
+0.84%
Mar 31, 2025
Morgan Stanley & Co. LLC
8.10M
6.44%
+40.85K
+0.51%
Mar 31, 2025
Deep Track Capital LP
7.00M
5.57%
+2.00M
+40.00%
May 09, 2025
BlackRock Institutional Trust Company, N.A.
5.43M
4.32%
-8.41K
-0.15%
Mar 31, 2025
AQR Capital Management, LLC
4.08M
3.24%
+2.22M
+119.64%
Mar 31, 2025
State Street Global Advisors (US)
3.94M
3.14%
-583.75K
-12.90%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Products ETF
1.73%
ALPS Medical Breakthroughs ETF
1.47%
Global X Guru Index ETF
1.21%
SPDR S&P Biotech ETF
0.63%
Direxion Daily S&P Biotech Bull 3X Shares
0.36%
Invesco Nasdaq Biotechnology ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.24%
iShares Biotechnology ETF
0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
First Trust Small Cap Growth AlphaDEX Fund
0.09%
View more
Virtus LifeSci Biotech Products ETF
Proportion1.73%
ALPS Medical Breakthroughs ETF
Proportion1.47%
Global X Guru Index ETF
Proportion1.21%
SPDR S&P Biotech ETF
Proportion0.63%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.36%
Invesco Nasdaq Biotechnology ETF
Proportion0.24%
ProShares Ultra Nasdaq Biotechnology
Proportion0.24%
iShares Biotechnology ETF
Proportion0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.09%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
